Skip to content

Study · Non-randomized trial · n = 8 · 1994

7 results

Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers.

Kuhn JM, Legrand A, Ruiz JM, Obach R, De Ronzan J, Thomas F

British journal of clinical pharmacology1 Sept 1994Cited by 30 (Europe PMC)

PMID7826822 (opens in a new tab)PMCIDPMC1364792 (opens in a new tab)DOI10.1111/j.1365-2125.1994.tb04344.x (opens in a new tab)PepBankPUB-07826822
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanNon-randomized trialPharmacokinetics

    In healthy men, plasma lanreotide reached 38.3 +/- 4.1 ng ml-1 at 2 h after injection.

    In plain wordsIn healthy men, plasma lanreotide reached 38.3 +/- 4.1 ng ml-1 at 2 h after injection.

    Peptide
    Lanreotide
    Outcome
    Not applicablePlasma concentration at 2 hours
    Study

    n = 8

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    30 mg · intramuscularAs given in this study (human).

    Measurements

    Plasma lanreotide peak concentration
    38.3 ng ml-1
    2 h after 30 mg SR-L injection; reported as +/- 4.1

    Source sentences

    Summary
    Plasma lanreotide concentrations rose to 38.3 +/- 4.1 ng ml-1 2 h following injection.
    2 context sentences
    Summary · context
    Eight healthy males were studied.
    Summary · context
    On day 1 of the study, 30 mg SR-L was administered intramuscularly.
  2. 02HumanNon-randomized trialPharmacokinetics

    In healthy men, lanreotide remained above 1.5 ng ml-1 until day 11 and reached 0.92 +/- 0.28 ng ml-1 after 2 weeks.

    In plain wordsIn healthy men, lanreotide stayed above 1.5 ng ml-1 until day 11 and reached 0.92 +/- 0.28 ng ml-1 at 2 weeks.

    Peptide
    Lanreotide
    Outcome
    Not applicablePlasma concentration persistence
    Study

    n = 8

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    30 mg · intramuscularAs given in this study (human).

    Measurements

    Plasma lanreotide concentration
    > 1.5 ng ml-1
    remained above until day 11
    Plasma lanreotide concentration
    0.92 ng ml-1
    2 weeks after injection; reported as +/- 0.28

    Source sentences

    Summary
    The levels then progressively decreased, remaining above 1.5 ng ml-1 until day 11 and reaching 0.92 +/- 0.28 ng ml-1 2 weeks after injection.
    2 context sentences
    Summary · context
    Eight healthy males were studied.
    Summary · context
    On day 1 of the study, 30 mg SR-L was administered intramuscularly.
  3. 03HumanNon-randomized trialPharmacokinetics

    In healthy men, lanreotide had an apparent plasma half-life of 4.52 +/- 0.50 days.

    In plain wordsIn healthy men, lanreotide had an apparent plasma half-life of 4.52 +/- 0.50 days.

    Peptide
    Lanreotide
    Outcome
    Not applicableApparent plasma half-life
    Study

    n = 8

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    30 mg · intramuscularAs given in this study (human).

    Measurements

    Apparent plasma half-life
    4.52 days
    reported as +/- 0.50

    Source sentences

    Summary
    The apparent plasma half-life and mean residence time were 4.52 +/- 0.50 and 5.48 +/- 0.51 days respectively.
    2 context sentences
    Summary · context
    Eight healthy males were studied.
    Summary · context
    On day 1 of the study, 30 mg SR-L was administered intramuscularly.
  4. 04HumanNon-randomized trialPharmacokinetics

    In healthy men, lanreotide had a mean residence time of 5.48 +/- 0.51 days.

    In plain wordsIn healthy men, lanreotide had a mean residence time of 5.48 +/- 0.51 days.

    Peptide
    Lanreotide
    Outcome
    Not applicableMean residence time
    Study

    n = 8

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    30 mg · intramuscularAs given in this study (human).

    Measurements

    Mean residence time
    5.48 days
    reported as +/- 0.51

    Source sentences

    Summary
    The apparent plasma half-life and mean residence time were 4.52 +/- 0.50 and 5.48 +/- 0.51 days respectively.
    2 context sentences
    Summary · context
    Eight healthy males were studied.
    Summary · context
    On day 1 of the study, 30 mg SR-L was administered intramuscularly.
  5. 05HumanNon-randomized trialEfficacy outcome

    In healthy men, insulin decreased only 2 h after lanreotide injection compared with the control day.

    In plain wordsIn healthy men, insulin decreased only 2 h after lanreotide injection compared with the control day.

    Peptide
    Lanreotide
    Outcome
    DecreaseInsulin
    Study

    n = 8

    Comparator
    Control day
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    30 mg · intramuscularAs given in this study (human).

    Source sentences

    Summary
    By comparison with the control day, plasma insulin concentrations only decreased 2 h following injection, whereas plasma glucagon did not change at any time.
    2 context sentences
    Summary · context
    Eight healthy males were studied.
    Summary · context
    On day 1 of the study, 30 mg SR-L was administered intramuscularly.
  6. 06HumanNon-randomized trialEfficacy outcome

    In healthy men, glucagon did not change after lanreotide injection compared with the control day.

    In plain wordsIn healthy men, glucagon did not change after lanreotide injection compared with the control day.

    Peptide
    Lanreotide
    Outcome
    No significant changeGlucagon
    Study

    n = 8

    Comparator
    Control day
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    30 mg · intramuscularAs given in this study (human).

    Source sentences

    Summary
    By comparison with the control day, plasma insulin concentrations only decreased 2 h following injection, whereas plasma glucagon did not change at any time.
    2 context sentences
    Summary · context
    Eight healthy males were studied.
    Summary · context
    On day 1 of the study, 30 mg SR-L was administered intramuscularly.
  7. 07HumanNon-randomized trialEfficacy outcome

    In healthy men, lanreotide reduced plasma TSH from 2 h through day 4 (P < 0.01).

    In plain wordsIn healthy men, lanreotide reduced plasma TSH from 2 h through day 4.

    Peptide
    Lanreotide
    Outcome
    DecreaseTSH
    Study

    n = 8

    Outcome group
    Thyroid function · Endocrine and hormones
    Studied dose
    30 mg · intramuscularAs given in this study (human).

    Source sentences

    Summary
    Plasma TSH concentrations were significantly (P < 0.01) reduced from 2 h to day 4 following SR-L injection.2+ '
    2 context sentences
    Summary · context
    Eight healthy males were studied.
    Summary · context
    On day 1 of the study, 30 mg SR-L was administered intramuscularly.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.